Key result
Ticagrelor linked to suspected acute hepatopathy that resolves upon drug discontinuation.
Why the study?
Despite ticagrelor's favorable safety profile, cases of ticagrelor-induced hepatotoxicity have been rarely reported and require further documentation.
Case Report (n=1)
This case report highlights the rare but potential risk of ticagrelor-induced hepatotoxicity, emphasizing the need for liver function monitoring.
Answers are grounded in this paper and cite their sources.
Warrants considering ticagrelor in hepatopathy differentials; single case leaves incidence and causality open.
Ticagrelor, a potent P2Y12 receptor inhibitor, is used widely to manage acute coronary syndrome owing to its superior efficacy in reducing cardiovascular events compared to clopidogrel. Despite its favorable safety profile, this paper reports a case of ticagrelor-induced hepatotoxicity. A 66-year-old male with a history of pituitary macroadenoma presented with elevated liver enzymes during a preoperative assessment for tumor removal. The patient was asymptomatic. Ultrasonography revealed diffusely decreased parenchymal echogenicity with prominent portal venular wall echogenicity, suggesting acute hepatopathy, while no significant findings were observed on the computed tomography image. All viral markers were negative; only the anti-nuclear antibody was positive. A biopsy was performed to discriminate autoimmune hepatitis. The specimen showed a lymphocytic infiltrate, with eosinophils and plasma cells mainly affecting the hepatic parenchyma in zone 3. The liver enzyme levels improved when the anti platelet drugs for biopsy were discontinued, but they worsened again after the biopsy. Hence, ticagrelor, an anti-platelet agent, was suspected as the causative drug. Ticagrelor was discontinued, and the subsequent liver enzyme levels gradually returned to normal. This case highlights the need for careful monitoring of the liver function in patients receiving ticagrelor.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) conducted a case report in Ticagrelor-induced hepatotoxicity (n=1). Ticagrelor was evaluated on Hepatotoxicity (elevated liver enzymes and acute hepatopathy). Ticagrelor was identified as the suspected cause of acute hepatopathy in a 66-year-old male, with liver enzymes normalizing upon discontinuation of the drug.
Synapse has enriched 10 related papers. Consider them for comparative context: